Application of Proteomics in Alzheimer’s Disease: A Mini Review
Main Article Content
Abstract
Alzheimer’s disease (AD) is classified as one of neurodegenerative disease caused by neuronal death. It is character- ized as memory impairment, including the inability to produce new memories. Since AD has low treatment effec- tiveness, proteomics research opens possibilities for advancement. Proteomics is the study of proteomes produced by the disease-bearing host to identify and understand diseases. In this case, to investigate the use of protein as a reliable molecular entity and their involvement in AD. Therefore, this review focused on three main applications of proteomics; the potential use of proteomics as a diagnostic tool for AD, the use of proteomics to assess the treatment progression of AD and the advancement in AD research. The review discussed three research areas utilizing the pro- teomics approach: ageing, behavioural, and demographic research of AD populations. Proteomic approaches have also been shown to be effective to discover the biomarkers for infectious diseases, cancers, heart diseases, and neuro- logical disorders. Although much work remained to be done, the proteomics approach is an interesting method to be carried out in detecting AD at an earlier stage and will be very useful for AD treatment and management in the future.
Downloads
Article Details
References
Moujalled, D., Strasser, A., & Liddell, J. R. (2021). Molecular mechanisms of cell death in neurological diseases. Cell Death & Differentiation 2021 28:7, 28(7), 2029–2044. doi:10.1038/s41418-021-00814-y
Pang, S. Y. Y., Teo, K. C., Hsu, J. S., Chang, R.S. K., Li, M., Sham, P. C., & Ho, S. L. (2017).The role of gene variants in the pathogenesis of neurodegenerative disorders as revealed by next generation sequencing studies: A review. Translational Neurodegeneration, 6(1), 1–11. doi:10.1186/S40035-017-0098-0/TABLES/3
Nuri, T. H. M., Hong, Y. H., Ming, L. C., Joffry, S. M., Othman, M. F., & Neoh, C. F. (2017). Knowledge on Alzheimer’s Disease among Public Hospitals and Health Clinics Pharmacists in the State of Selangor, Malaysia. Frontiers in Pharmacology, 8(OCT), 739. doi:10.3389/FPHAR.2017.00739
Magalingam, K. B., Radhakrishnan, A., Ping, N. S., & Haleagrahara, N. (2018). Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease. BioMed Research International, 2018. doi:10.1155/2018/3740461
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., Awasthi, A., Barker-Collo, S. L., Baune, B. T., Béjot, Y., Belachew, A. B., Bennett, D. A., Biadgo, B., Bijani, A., Bin Sayeed, M. S., … Murray, C. J.
L. (2019). Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990– 2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(1), 88–106. doi:10.1016/S1474-4422(18)30403-4
Jagust, W. (2018). Imaging the evolution and pathophysiology of Alzheimer disease. Nature Reviews Neuroscience, 19(11), 687–700. doi:10.1038/S41583-018-0067-3
Long, J. M., & Holtzman, D. M. (2019). Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 179(2), 312–339. doi:10.1016/J. CELL.2019.09.001
Hamezah, H. S., Durani, L. W., Yanagisawa, D., Ibrahim, N. F., Aizat, W. M., Bellier, J. P., Makpol, S., Ngah, W. Z. W., Damanhuri, H. A., & Tooyama, I. (2018). Proteome profiling in the hippocampus, medial prefrontal cortex, and striatum of aging rat. Experimental Gerontology, 111(May), 53–64. doi:10.1016/j.exger.2018.07.002
Gaubert, F., & Chainay, H. (2021). Decision-Making Competence in Patients with Alzheimer’s Disease: A Review of the Literature. Neuropsychology Review, 31(2), 267–287. doi:10.1007/S11065-020-09472-2
Joe, E., & Ringman, J. M. (2019). Cognitive symptoms of Alzheimer’s disease: Clinical management and prevention. BMJ, 367. doi:10.1136/BMJ.L6217
Botchway, B. O., Okoye, F. C., Chen, Y., Arthur, W. E., & Fang, M. (2022). Alzheimer Disease: Recent Updates on Apolipoprotein E and Gut Microbiome Mediation of Oxidative Stress, and Prospective Interventional Agents. Aging and Disease, 13(1), 87. doi:10.14336/AD.2021.0616
Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nature Reviews Neuroscience, 20(3), 148–160. doi:10.1038/S41583-019-0132-6
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C. C., & Bu, G. (2019). Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nature Reviews Neurology, 15(9), 501–518. doi:10.1038/s41582-019-0228-7
Aslam, B., Basit, M., Nisar, M. A., Khurshid, M., & Rasool, M. H. (2017). Proteomics: Technologies and Their Applications. Journal of Chromatographic Science, 55(2), 182–196. doi:10.1093/CHROMSCI/BMW167
Jungblut, P. R., Holzhütter, H. G., Apweiler, R., & Schlüter, H. (2008). The speciation of the proteome. Chemistry Central Journal, 2(1), 1–10. doi:10.1186/1752-153X-2-16/FIGURES/6
Grant, Seth G. N.; Blackstock, Walter P. (2001). Proteomics in Neuroscience: From Protein to Network. The Journal of Neuroscience, 21(21), 8315–8318. doi:10.1523/ jneurosci.21-21-08315.2001
Westermarck, J., Ivaska, J., & Corthals, G. L. (2013). Identification of Protein Interactions Involved in Cellular Signaling. Molecular & Cellular Proteomics: MCP, 12(7), 1752. doi:10.1074/MCP. R113.027771
Cox, J., & Mann, M. (2007). Is Proteomics the New Genomics? Cell, 130(3), 395–398. doi:10.1016/ J.CELL.2007.07.032/ATTACHMENT/6E54EAEC- 2B6E-4481-9C6E-697819079E83/MMC3.XLS
Cristea, I. M., Gaskell, S. J., & Whetton, A. D. (2004). Proteomics techniques and their application to hematology. Blood, 103(10), 3624–3634. doi:10.1182/BLOOD-2003-09-3295
Sidoli, S., Kulej, K., & Garcia, B. A. (2017). Why proteomics is not the new genomics and the future of mass spectrometry in cell biology. Journal of Cell Biology, 216(1), 21–24. doi:10.1083/ JCB.201612010
Suppers, A., van Gool, A. J., & Wessels, H. J. C. T. (2018). Integrated Chemometrics and Statistics to Drive Successful Proteomics Biomarker Discovery. Proteomes 2018, Vol. 6, Page 20, 6(2), 20. doi:10.3390/PROTEOMES6020020
Yokota, H. (2019). Applications of proteomics in pharmaceutical research and development. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1867(1), 17–21. doi:10.1016/J. BBAPAP.2018.05.008
Kolch, Walter; Pitt, Andrew (2010). Functional proteomics to dissect tyrosine kinase signalling pathways in cancer., 10(9), 618–629. doi:10.1038/ nrc2900
Pan, J., Hu, Y., Sun, S., Chen, L., Schnaubelt, M., Clark, D., Ao, M., Zhang, Z., Chan, D., Qian, J., & Zhang, H. (2020). Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer. Nature Communications, 11(1). doi:10.1038/ s41467-020-19976-3
Kondrat F.D.L., Struwe W.B., Benesch J.L.P. (2015) Native Mass Spectrometry: Towards High- Throughput Structural Proteomics. In: Owens R. (eds) Structural Proteomics. Methods in Molecular Biology, vol 1261. Humana Press, New York, NY. doi:10.1007/978-1-4939-2230-7_18
Wright, E. P., Partridge, M. A., Padula, M. P., Gauci, V. J., Malladi, C. S., & Coorssen, J. R. (2014). Top-down proteomics: enhancing 2D gel electrophoresis from tissue processing to high- sensitivity protein detection. Proteomics, 14(7-8), 872-889. doi:10.1002/pmic.201300424
Mahmood, T., & Yang, P. C. (2012). Western blot: technique, theory, and trouble shooting. North American Journal of Medical Sciences, 4(9), 429–434. doi:10.4103/1947-2714.100998
Huang, R., Chen, Z., He, L., He, N., Xi, Z., Li, Z., Deng, Y., & Zeng, X. (2017). Mass spectrometry- assisted gel-based proteomics in cancer biomarker discovery: Approaches and application. Theranostics, 7(14), 3559–3572. doi:10.7150/ THNO.20797
Ho, A. M. C., Cabello-Arreola, A., Markota, M., Heppelmann, C. J., Charlesworth, M. C., Ozerdem, A., Mahajan, G., Rajkowska, G., Stockmeier, C. A., Frye, M. A., Choi, D. S., & Veldic, M. (2020). Label-free proteomics differences in the dorsolateral prefrontal cortex between bipolar disorder patients with and without psychosis. Journal of Affective Disorders, 270, 165–173.doi:10.1016/J. JAD.2020.03.105
Jacob, J., Ngo, D., Finkel, N., Pitts, R., Gleim, S., Benson, M. D., Keyes, M. J., Farrell, L. A., Morgan, T., Jennings, L. L., & Gerszten, R. E. (2018). Application of large-scale aptamer- based proteomic profiling to planned myocardial infarctions. Circulation, 137(12), 1270–1277. doi:10.1161/CIRCULATIONAHA.117.029443
Fountoulakis, M. (2004). Application of proteomics technologies in the investigation of the brain. Mass Spectrometry Reviews, 23(4), 231–258. doi:10.1002/MAS.10075
Zhang, L., Li, Y., & Gao, Y. (2018). Early changes in the urine proteome in a diethyldithiocarbamate- induced chronic pancreatitis rat model. Journal of Proteomics, 186, 8–14. doi:10.1016/J. JPROT.2018.07.015
Henriksen, K., O’Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss-Coray, T., Soares, H., Bazenet, C., Sjögren, M., Hu, W., Lovestone, S., Karsdal, M. A., & Weiner, M. W. (2013). Blood-Based Biomarker Interest Group. The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement. 2014 Jan;10(1):115-31. doi: 10.1016/j.jalz.2013.01.013. Epub 2013 Jul 11. PMID: 23850333; PMCID: PMC4128378.
Graves, P. R., & Haystead, T. A. J. (2002). Molecular Biologist’s Guide to Proteomics. Microbiology and Molecular Biology Reviews, 66(1), 39. doi:10.1128/MMBR.66.1.39-63.2002
Hedl, T. J., Gil, R. S., Cheng, F., Rayner, S. L., Davidson, J. M., Luca, A. De, Villalva, M. D., Ecroyd, H., Walker, A. K., & Lee, A. (2019). Proteomics approaches for biomarker and drug target discovery in als and ftd. Frontiers in Neuroscience, 13(JUN),548. doi:10.3389/FNINS.2019.00548/BIBTEX
Yanagida, M. (2002). Functional proteomics; current achievements. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 771(1–2), 89–106. doi:10.1016/ S1570-0232(02)00074-0
Föcking, M., Dicker, P., Lopez, L. M., Hryniewiecka, M., Wynne, K., English, J. A., Cagney, G., & Cotter, D. R. (2016). Proteomic analysis of the postsynaptic density implicates synaptic function and energy pathways in bipolar disorder. Translational Psychiatry, 6(11), e959. doi:10.1038/TP.2016.224
Whitelegge, J. P. (2013). Integral Membrane Proteins and Bilayer Proteomics. Analytical Chemistry, 85(5), 2558–2568. doi:10.1021/AC303064A
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 14(11), 639–652. doi:10.1038/S41582-018-0079-7
Morgan, A. R., Touchard, S., Leckey, C., O’Hagan, C., Nevado-Holgado, A. J., Barkhof, F., Bertram, L., Blin, O., Bos, I., Dobricic, V., Engelborghs, S., Frisoni, G., Frölich, L., Gabel, S., Johannsen, P., Kettunen, P., Kłoszewska, I., Legido-Quigley, C., Lleó, A., … Mount, H. (2019). Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimer’s & Dementia, 15(6), 776–787. doi:10.1016/J.JALZ.2019.03.007
Santaella, A., Kuiperij, H. B., Van Rumund, A., Esselink, R. A. J., Van Gool, A. J., Bloem, B. R., & Verbeek, M. M. (2020). Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms. BMC Neurology, 20(1), 1–8. doi:10.1186/S12883-020-1608-8/FIGURES/2
Mumtaz, M. W., Hamid, A. A., Akhtar, M. T., Anwar, F., Rashid, U., & Al-Zuaidy, M. H. (2017). An overview of recent developments in metabolomics and proteomics – phytotherapic research perspectives. Https://Doi.Org/10.1080/21 553769.2017.1279573, 10(1), 1–37. doi:10.1080/21553769.2017.1279573
Rehiman, S. H., Lim, S. M., Lim, F. T., Chin, A. V., Tan, M. P., Kamaruzzaman, S. B., Ramasamy, K., & Abdul Majeed, A. B. (2020). Fibrinogen isoforms as potential blood-based biomarkers of Alzheimer’s disease using a proteomics approach. International Journal of Neuroscience, 0(0), 1–12. doi:10.1080/00207454.2020.1860038
Al-Wajeeh, A. S., Salhimi, S. M., Al-Mansoub, M. A., Khalid, I. A., Harvey, T. M., Latiff, A., & Ismail, M. N. (2020). Comparative proteomic analysis of different stages of breast cancer tissues using ultra high performance liquid chromatography tandem mass spectrometer. PLOS ONE, 15(1), e0227404. doi:10.1371/JOURNAL.PONE.0227404
Lee, L. P., Tan, K. Y., & Tan, C. H. (2021). Snake venom proteomics and antivenomics of two Sundaic lance-headed pit vipers: Trimeresurus wiroti (Malaysia) and Trimeresurus puniceus (Indonesia). Comparative Biochemistry and Physiology Part D: Genomics and Proteomics, 40, 100875. doi:10.1016/J.CBD.2021.100875
Bai, B., Wang, X., Li, Y., Chen, P. C., Yu, K., Dey, K. K., Yarbro, J. M., Han, X., Lutz, B. M., Rao, S.,Jiao, Y., Sifford, J. M., Han, J., Wang, M., Tan, H., Shaw, T. I., Cho, J. H., Zhou, S., Wang, H., … Peng, J. (2020). Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression. Neuron, 105(6), 975-991.e7. doi:10.1016/J.NEURON.2019.12.01547.
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P. C., Yang, K., & Peng, J. (2021). Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery. Molecular Neurodegeneration 2021 16:1, 16(1), 1–16. doi:10.1186/S13024-021-00474-Z
Salama, M., Shalash, A., Magdy, A., Makar, M., Roushdy, T., Elbalkimy, M., Elrassas, H., Elkafrawy, P., Mohamed, W., & Abou Donia, M. B. (2018). Tubulin and Tau: Possible targets for diagnosis of Parkinson’s and Alzheimer’s diseases. PLOS ONE, 13(5), e0196436. doi:10.1371/JOURNAL. PONE.0196436
Maji, S. K., Anoop, A., Singh, P. K., & Jacob, R. S. (2010). CSF Biomarkers for Alzheimer’s Disease Diagnosis. International Journal of Alzheimer’s Disease, 2010. doi:10.4061/2010/606802
Sharma, N., & Singh, A. N. (2016). Exploring Biomarkers for Alzheimer’s Disease. Journal of Clinical and Diagnostic Research: JCDR, 10(7), KE01. doi:10.7860/JCDR/2016/18828.8166
Janelidze, S., Mattsson, N., Stomrud, E., Lindberg, O., Palmqvist, S., Zetterberg, H., Blennow, K., & Hansson, O. (2018). CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, e867–e877. doi:10.1212/ WNL.0000000000006082
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019). VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD. Alzheimer Disease and Associated Disorders, 33(4), 307–314. doi:10.1097/WAD.0000000000000328
Van Steenoven, I., Noli, B., Cocco, C., Ferri, G. L., Oeckl, P., Otto, M.,... & Teunissen, C. E. (2019). VGF peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. International Journal of Molecular Sciences, 20(19), 4674. doi:10.3390/ ijms20194674
Wingo, A. P., Dammer, E. B., Breen, M. S., Logsdon, B. A., Duong, D. M., Troncosco, J. C., ... & Wingo, T. S. (2019). Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age. Nature Communications, 10(1), 1-14. doi:10.1038/ s41467-019-09613-z
Quinn, J. P., Kandigian, S. E., Trombetta, B. A., Arnold, S. E., & Carlyle, B. C. (2021). VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. Brain Communications, 3(4). doi:10.1093/ BRAINCOMMS/FCAB261
Busse, S., Steiner, J., Glorius, S., Dobrowolny, H., Greiner-Bohl, S., Mawrin, C., Bommhardt, U., Hartig, R., Bogerts, B., & Busse, M. (2015). VGF expression by T lymphocytes in patients with Alzheimer’s disease. Oncotarget. 2015 Jun 20;6(17):14843-51. doi: 10.18632/oncotarget.3569.
Cocco, C., D’Amato, F., Noli, B., Ledda, A., Brancia, C., Bongioanni, P., & Ferri, G. L. (2010). Distribution of VGF peptides in the human cortex and their selective changes in Parkinson’s and Alzheimer’s diseases. Journal of Anatomy, 217(6), 683-693. doi:10.1111/j.1469-7580.2010.01309.x
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015). Biomarkers in Sporadic and Familial Alzheimer’s Disease. Journal of Alzheimer’s Disease, 47(2), 291–317. doi:10.3233/JAD-143006
Goodman, I. J. (2008). Practical utility of urinary assay in the diagnosis of Alzheimer’s disease: AlzheimAlertTM. Expert Review of Molecular Diagnostics, 8(1), 21–28. doi:10.1586/14737159.8.1.21
Ma, L., Chen, J., Wang, R., Han, Y., Zhang, J., Dong, W., Zhang, X., Wu, Y., & Zhao, Z. (2015). The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. Journal of Clinical Neuroscience, 22(4), 649–652. doi:10.1016/J. JOCN.2014.10.011
Jin, H., & Wang, R. (2021). Alzheimer-Associated Neuronal Thread Protein: Research Course and Prospects for the Future. Journal of Alzheimer’s Disease, 80, 963–971. doi:10.3233/JAD-201273
Ziemann, U., Wahl, M., Hattingen, E., & Tumani, H. (2011). Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Prog Neurobiol. 2011 Dec;95(4):670-85. doi: 10.1016/j.pneurobio.2011.04.007. Epub 2011 Apr 16. PMID: 21524682.
Jeter, C. B., Hergenroeder, G. W., Hylin, M. J., Redell, J. B., Moore, A. N., & Dash, P. K. (2013). Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion. J Neurotrauma. 2013 Apr 15;30(8):657-70. doi: 10.1089/neu.2012.2439. PMID: 23062081.
Thambisetty, M., & Lovestone, S. (2010). Blood- based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark Med, 4(1), 65–79. doi: 10.2217/bmm.09.84
Rehiman, S. H., Lim, S. M., Neoh, C. F., Majeed, A. B. A., Chin, A. V., Tan, M. P., Kamaruzzaman, S. B., & Ramasamy, K. (2020). Proteomics as a reliable approach for discovery of blood-based Alzheimer’s disease biomarkers: A systematic review and meta- analysis. Ageing Research Reviews, 60, 101066. doi:10.1016/J.ARR.2020.101066
Altuna-Azkargorta, M., & Mendioroz-Iriarte, M. (2021). Blood biomarkers in Alzheimer’s disease. Neurología (English Edition), 36(9), 704–710. doi:10.1016/J.NRLENG.2018.03.006
Doig, A. J., Del Castillo-Frias, M. P., Berthoumieu, O., Tarus, B., Nasica-Labouze, J., Sterpone, F., et al. (2017). Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer’s Disease? ACS Chem. Neurosci. 8 (7), 1435–1437. doi: 10.1021/ acschemneuro.7b00188
Ibrahim, N. H., Yahaya, M. F., Mohamed, W., Teoh, S. L., Hui, C. K., & Kumar, J. (2020). Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty. Front. Pharmacol. 11:261. doi: 10.3389/fphar.2020.00261
Thambisetty, M., Simmons, A., Hye, A., Campbell, J., Westman, E., Zhang, Y., Wahlund, L. O., Kinsey, A., Causevic, M., Killick, R., Kloszewska, I., Mecocci, P., Soininen, H., Tsolaki, M., Vellas, B., Spenger, C., & Lovestone, S. (2011). Plasma Biomarkers of Brain Atrophy in Alzheimer’s Disease. PLOS ONE, 6(12), e28527. doi:10.1371/ JOURNAL.PONE.0028527
Doecke, J. D., Laws, S. M., Faux, N. G., Wilson, W., Burnham, S. C., Lam, C. P., Mondal, A., Bedo, J., Bush, A. I., Brown, B., De Ruyck, K., Ellis, K. A., Fowler, C., Gupta, V. B., Head, R., Macaulay, S. L., Pertile, K., Rowe, C. C., Rembach, A., … Martins, R. N. (2012). Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Archives of Neurology, 69(10), 1318–1325. doi:10.1001/ ARCHNEUROL.2012.1282
Hertze, J., Nägga, K., Minthon, L., & Hansson, O. (2014). Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: An observational study. BMC Neurology, 14(1), 1–8. doi:10.1186/1471-2377- 14-64/TABLES/4
Kitamura, Y., Usami, R., Ichihara, S., Kida, H., Satoh, M., Tomimoto, H., Murata, M., & Oikawa, S. (2017). Plasma protein profiling for potential biomarkers in the early diagnosis of Alzheimer’s disease. doi:10.1080/01616412.2017.1281195, 39(3), 231–238.
Gupta, V. B., Hone, E., Pedrini, S., Doecke, J., O’Bryant, S., James, I., Bush, A. I., Rowe, C. C., Villemagne, V. L., Ames, D., Masters, C. L., & Martins, R. N. (2017). Altered levels of blood proteins in Alzheimer’s disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 8, 60. doi:10.1016/J.DADM.2017.04.003
Sun, Y., Li, Q., Liu, W., & Zhang, B. (2020). Relationship between fibrinogen level and its regulatory gene with Alzheimer’s disease and vascular dementia. Journal of International Medical Research, 48(2), 1–12. doi:10.1177/0300060520902578
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., Mattsson- Carlgren, N., Strandberg, O., Smith, R., Villegas, A., Sepulveda-Falla, D., Chai, X., Proctor, N. K., Beach, T. G., Blennow, K., … Hansson,
O. (2020). Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 324(8), 772–781. doi:10.1001/JAMA.2020.12134
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020). Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. Journal of Experimental Medicine, 217(11). doi:10.1084/JEM.20200861
Shi, L., Buckley, N. J., Bos, I., Engelborghs, S., Sleegers, K., Frisoni, G. B., Wallin, A., Lléo, A., Popp, J., Martinez-Lage, P., Legido-Quigley, C., Barkhof, F., Zetterberg, H., Visser, P. J., Bertram, L., Lovestone, S., & Nevado-Holgado, A. J. (2021). Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 13. doi:10.3389/FNAGI.2021.712545/FULL
Chatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., Zetterberg, H., Blennow, K., Teunissen, C. E., Vanderstichele, H. M., & Martins, R. N. (2021). Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Translational Psychiatry, 11(1). doi:10.1038/ S41398-020-01137-1
Park, J. E., Gunasekaran, T. I., Cho, Y. H., Choi, S.-M.,Song, M.-K., Cho, S. H., Kim, J.,Song, H.-C., Choi, K. Y., Lee, J. J., Park, Z.-Y.,Song,
W. K., Jeong, H.-S., Lee, K. H., Lee, J. S., & Kim, B. C. (2022). Diagnostic Blood Biomarkers in Alzheimer’s Disease. Biomedicines, 10(1), 169. doi:10.3390/biomedicines10010169
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018). Liposome delivery systems for the treatment of Alzheimer’s disease. International Journal of Nanomedicine, 13, 8507–8522. doi:10.2147/ IJN.S183117
Yahaya, M. A. F., Zolkiffly, S. Z. I., Moklas, M. A.M., Hamid, H. A., Stanslas, J., Zainol, M., & Mehat, M. Z. (2020). Possible Epigenetic Role of Vitexin in Regulating Neuroinflammation in Alzheimer’s Disease. Journal of Immunology Research, 2020, 1–7. doi:10.1155/2020/946921010.1155/2020/9469210
Abubakar, M. B., Sanusi, K. O., Ugusman, A., Mohamed, W., Kamal, H., Ibrahim, N. H., Khoo, C. S., & Kumar, J. (2022). Alzheimer’s Disease: An Update and Insights Into Pathophysiology. Front. Ageing Neurosci. 14:742408. doi: 10.3389/ fnagi.2022.742408
Hamezah, H. S., Durani, L. W., Yanagisawa, D., Ibrahim, N. F., Aizat, W. M., Makpol, S., Wan Ngah, W. Z., Damanhuri, H. A., & Tooyama, I. (2019). Modulation of Proteome Profile in AβPP/ PS1 Mice Hippocampus, Medial Prefrontal Cortex, and Striatum by Palm Oil Derived Tocotrienol- Rich Fraction. Journal of Alzheimer’s Disease, 72(1), 229–246. doi:10.3233/JAD-181171
Rahman, M. A. (2020). Ganoderma lucidum Modulates Neuronal Distorted Cytoskeletal Proteomics and Protein-Protein Interaction in Alzheimer’s Disease Model Animals. Archives in Neurology & Neuroscience, 9(3). doi: 10.33552/ ANN.2020.09.000713
Mohd Hasni, D. S., Lim, S. M., Chin, A. V., Tan, M. P., Poi, P. J. H., Kamaruzzaman, S. B., Majeed, A. B. A., and Ramasamy, K. (2017). Peripheral cytokines, C-X-C motif ligand10 and interleukin-13, are associated with Malaysian Alzheimer’s disease. Geriatr Gerontol Int, 17: 839– 846. doi: 10.1111/ ggi.12783.
Papassotiropoulos, A., Fountoulakis, M., Dunckley, T., Stephan, D. A., & Reiman, E. M. (2006). Genetics, transcriptomics, and proteomics of Alzheimer’s disease. J Clin Psychiatry. 2006 Apr;67(4):652-70. doi: 10.4088/jcp.v67n0418. PMID: 16669732; PMCID: PMC2259384.
Shimizu, S., (2022). Imaging Life. siemens- healthineers.com/NMNS
Drummond, E., & Wisniewski, T. (2019). Using Proteomics to Understand Alzheimer’s Disease Pathogenesis. In Alzheimer’s Disease (pp. 37–51). Codon Publications. doi:10.15586/ ALZHEIMERSDISEASE.2019.CH3
Xia, X., Jiang, Q., McDermott, J., & Han, J. D. J. (2018). Aging and Alzheimer’s disease: Comparison and associations from molecular to system level. Aging Cell, 17(5), e12802. doi:10.1111/ ACEL.12802
Genon, S., Reid, A., Langner, R., Amunts, K., & Eickhoff, S. B. (2018). How to Characterize the Function of a Brain Region. Trends in Cognitive Sciences, 22(4), 350–364. doi:10.1016/J. TICS.2018.01.010
Li, Y., Li, Y., Yu, H., Yu, H., Chen, C., Chen, C., Li, S., Zhang, Z., Xu, H., Zhu, F., Liu, J., Liu, J., Spencer, P. S., Dai, Z., & Yang, X. (2020). Proteomic Profile of Mouse Brain Aging Contributions to Mitochondrial Dysfunction, DNA Oxidative Damage, Loss of Neurotrophic Factor, and Synaptic and Ribosomal Proteins. Oxidative Medicine and Cellular Longevity, 2020. doi:10.1155/2020/5408452
Manavalan, A., Mishra, M., Feng, L., Sze, S. K., Akatsu, H., & Heese, K. (2013). Brain site-specific proteome changes in aging-related dementia. Experimental & Molecular Medicine 2013 45:9, 45(9), e39–e39. doi:10.1038/emm.2013.76
Duda, P., Wójcicka, O., Wisniewski, J. R., & Rakus, D. (2018). Global quantitative TPA-based proteomics of mouse brain structures reveals significant alterations in expression of proteins involved in neuronal plasticity during aging. Aging, 10(7), 1682–1697. doi:10.18632/AGINH.101501
Cabral-Miranda, F., Tamburini, G., Martinez, G., Medinas, D., Gerakis, Y., Miedema, T., Duran-Aniotz, C., Ardiles, A. O., Gonzalez, C., Sabusap, C., Bermedo-Garcia, F., Adamson, S., Vitangcol, K., Huerta, H., Zhang, X., Nakamura, T., Sardi, S. P., Lipton, S. A., Kenedy, B. K., … Affiliations, *. (2020). Control of mammalian brain aging by the unfolded protein response (UPR). BioRxiv, 2020.04.13.039172. doi:10.1101/2020.04.13.039172
Bakar, Z. H. A., Damanhuri, H. A., Makpol, S., Kamaruddin, W. M. A. W., Sani, N. F. A., Hamzah, A. I. Z. A., Aripin, K. N. N., Rani, M. D. M., Noh, N. A., Razali, R., Mazlan, M., Hamid, H. A., Mohamad, M., & Ngah, W. Z. W. (2019). Effect of Age on the Protein Profile of Healthy Malay Adults and its Association with Cognitive Function Competency. Journal of Alzheimer’s Disease, 70(s1), S43–S62. doi:10.3233/JAD-180511
Whitson, H. E., Cohen, H. J., Schmader, K. E., Morey, M. C., Kuchel, G., & Colon-Emeric, C.S. (2018). Physical Resilience: Not Simply the Opposite of Frailty. Journal of the American Geriatrics Society, 66(8), 1459. doi:10.1111/ JGS.15233
Gopinath, B., Kifley, A., Flood, V. M., & Mitchell, P. (2018). Physical Activity as a Determinant of Successful Aging over Ten Years. Scientific Reports 2018 8:1, 8(1), 1–5. doi: 10.1038/s41598-018-28526-3
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N.(2010). A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 2010; 68: 930–941. doi: 10.1016/j. biopsych.2010.06.012.
Mu, Y., & Gage, F. H. (2011). Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Molecular Neurodegeneration, 6(1), 1–9. doi:10.1186/1750-1326-6-85/TABLES/1
Li, M., Lyu, J. H., Zhang, Y., Gao, M. L., Li, R., Mao, P. X., Li, W. J., & Ma, X. (2020). Efficacy of Group Reminiscence Therapy on Cognition, Depression, Neuropsychiatric Symptoms, and Activities of Daily Living for Patients With Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 33(5), 272–281. doi:10.1177/0891988719882099
Rahman, M. A., Hossain, S., Abdullah, N., & Aminudin, N. (2019). Brain proteomics links oxidative stress with metabolic and cellular stress response proteins in behavioural alteration of Alzheimer’s disease model rats. AIMS Neuroscience, 6(4), 299. doi:10.3934/NEUROSCIENCE.2019.4.299
Bac, B., Hicheri, C., Weiss, C., Buell, A. Vilcek, N., Spaeni, C., Geula, C., Savas, J. N., & Disterhoft, J. F. (2022). The TgF344-AD Rat: Behavioral and Proteomic Changes Associated with Ageing and Protein Expression in a Transgenic Rat Model of Alzheimer’s Disease. Neurobiology of Ageing. 2022. ISSN 0197-4580, doi:10.1016/j.neurobiolageing.2022.12.015.
Nie, L., Wei, G., Peng, S., Qu, Z., Yang, Y., Yang, Q., Huang, X., Liu, J., Zhuang, Z., & Yang, X. (2017). Melatonin ameliorates anxiety and depression- like behaviors and modulates proteomic changes in triple transgenic mice of Alzheimer’s disease. Biofactors. 2017 Jul 8;43(4):593-611. doi: 10.1002/ biof.1369. Epub 2017 Jun 13. PMID: 28608594.
Patil, G., Kulsange, S., Kazi, R., Chirmade, T., Kale, V., Mote, C., Aswar, M., Koratkar, S., Agawane, S., & Kulkarni, M. (2022). ACS Pharmacology & Translational Science doi: 10.1021/ acsptsci.2c00143
Amiri-Dashatan, N., Koushki, M., Abbaszadeh, H. A., Rostami-Nejad, M., & Rezaei-Tavirani, M. (2018). Proteomics Applications in Health: Biomarker and Drug Discovery and Food Industry. Iranian Journal of Pharmaceutical Research: IJPR, 17(4), 1523. doi:10.22037/IJPR.2018.2306
Al Shweiki, M. R., Steinacker, P., Oeckl, P., Hengerer, B., Danek, A., Fassbender, K., Diehl- Schmid, J., Jahn, H., Anderl-Straub, S., Ludolph,
A. C., Schönfeldt-Lecuona, C., & Otto, M. (2019). Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 113, 137–140. doi:10.1016/J. JPSYCHIRES.2019.03.019
Dodig-Crnković, T., Hong, M. G., Thomas, C. E., Häussler, R. S., Bendes, A., Dale, M., Edfors, F., Forsström, B., Magnusson, P. K. E., Schuppe-Koistinen, I., Odeberg, J., Fagerberg, L., Gummesson, A., Bergström, G., Uhlén, M., & Schwenk, J. M. (2020). Facets of individual-specific health signatures determined from longitudinal plasma proteome profiling. EBioMedicine, 57, 102854. doi:10.1016/J.EBIOM.2020.102854
Gebert, N., Cheng, C. W., Kirkpatrick, J. M., Di Fraia, D., Yun, J., Schädel, P., Pace, S., Garside, G. B., Werz, O., Rudolph, K. L., Jasper, H., Yilmaz, Ö. H., & Ori, A. (2020). Region-Specific Proteome Changes of the Intestinal Epithelium during Aging and Dietary Restriction. Cell Reports, 31(4), 107565. doi:10.1016/J.CELREP.2020.107565